285 completed, 84 terminated, 42 unknown, 20 active not recruiting. 275 Phase 2, 105 Phase 1, 51 Phase 3, 23 Not applicable, 9 Phase 4.
Follow Sunitinib: new trials by email Literature Review of Sunitinib trials Research Report on Sunitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma Methotrexate, Doxorubicin, Cisplatin - Osteosarcoma, Metastasis | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2026-03-11 | 2026-03-17 |
| A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy IDRX-42, Sunitinib - Gastrointestinal Neoplasms | Phase 3 | Recruiting | GlaxoSmithKline | 450 | 2025-12-03 | 2026-10-05 |
| A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI Vorolanib Tablets+Everolimus, Sunitinib - Renal Cell Carcinoma (RCC) | Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 116 | 2025-09-25 | 2025-09-10 |
| Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment [177Lu]Lu-DOTATATE, Standard of Care treatments - Intracranial Meningioma | Phase 2 | Recruiting | RTOG Foundation, Inc. | 130 | 2025-08-24 | 2026-10-02 |
| Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell Carcinoma Benmelstobart, Anlotinib, Sunitinib - Non-Clear Cell Renal Cell Carcinoma | Phase 3 | Active not recruiting | Sun Yat-sen University | 126 | 2025-06-01 | 2026-10-20 |
| 177Lu-DOTATATE for Recurrent Meningioma Local standard of Care, 177Lu-DOTATATE - Recurrent Meningioma | Phase 2 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 136 | 2025-03-10 | 2026-06-15 |
| Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC Bicalutamide in combination with Sunitinib - Carcinoma, Renal Cell | Phase 1 / Phase 2 | Recruiting | State University of New York at Buffalo | 28 | 2024-10-01 | 2026-04-01 |
| Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study) Stereotactic body radiotherapy (SBRT), axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib - Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic | Phase 3 | Recruiting | Sun Yat-sen University | 252 | 2024-09-18 | 2026-01-15 |
| Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate - Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 24 | 2024-08-14 | 2026-10-20 |
| SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST Bezuclastinib in combination with sunitinib - Gastrointestinal Stromal Tumors, GIST | Phase 2 | Active not recruiting | Sarcoma Alliance for Research through Collaboration | 40 | 2024-08-01 | 2025-10-31 |
| OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults Olaparib, Lenvatinib, Sunitinib - Renal Cell Carcinoma, Ovarian Carcinoma | Phase 4 | Unknown | University Medical Center Groningen | 30 | 2024-05-01 | 2023-11-29 |
| Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial Biospecimen Collection, Cabozantinib, Computed Tomography - Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 100 | 2024-01-12 | 2026-10-28 |
| A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib Ripretinib, Sunitinib - GIST | Phase 3 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 54 | 2023-12-13 | 2025-12-17 |
| ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST Sunitinib, Regorafenib - Gastrointestinal Stromal Tumors | Phase 2 | Recruiting | University of Miami | 48 | 2023-10-17 | 2026-10-23 |
| Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment Sunitinib - Renal Cell Carcinoma | Not applicable | Not yet recruiting | First Affiliated Hospital, Sun Yat-Sen University | 488 | 2023-10-01 | 2023-09-13 |
| A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine. Sunitinib - Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma | Completed | Pfizer | 376 | 2023-02-23 | 2024-08-05 | |
| Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib - Gastrointestinal Stromal Tumors | Not applicable | Recruiting | Xiangya Hospital of Central South University | 258 | 2023-02-01 | 2023-03-02 |
| Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma XL092, Nivolumab, Sunitinib Malate - Non-Clear Cell Renal Cell Carcinoma | Phase 3 | Active not recruiting | Exelixis | 317 | 2023-01-01 | 2026-07-29 |
| Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World Avapritinib, Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al ) - Gastrointestinal Stromal Tumors | Completed | CStone Pharmaceuticals | 61 | 2022-08-29 | 2026-02-11 | |
| Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma sunitinib or pazopanib, PD-1 inhibitor combined with axitinib - Metastatic Renal Cell Carcinoma | Not applicable | Unknown | RenJi Hospital | 500 | 2022-08-01 | 2023-04-18 |
Showing 20 of 464. Sign in to see all of them.
Carcinoma, Renal Cell (145) · Kidney Neoplasms (42) · Neoplasms (39) · Neoplasm Metastasis (35) · Breast Neoplasms (33) · Gastrointestinal Stromal Tumors (31) · Carcinoma, Non-Small-Cell Lung (22) · Prostatic Neoplasms (16) · Urinary Bladder Neoplasms (13) · Brain Neoplasms (12) · Colorectal Neoplasms (12) · Carcinoma, Hepatocellular (11) · Glioblastoma (11) · Pancreatic Neoplasms (11) · Carcinoma (10)
Pfizer (86) · National Cancer Institute (NCI) (42) · M.D. Anderson Cancer Center (13) · Memorial Sloan Kettering Cancer Center (10) · Amsterdam UMC, location VUmc (7) · Case Comprehensive Cancer Center (6) · Massachusetts General Hospital (6) · Assistance Publique - Hôpitaux de Paris (5) · Duke University (5) · H. Lee Moffitt Cancer Center and Research Institute (5) · Novartis Pharmaceuticals (5) · Samsung Medical Center (5) · University Health Network, Toronto (5) · Bristol-Myers Squibb (4) · Central European Society for Anticancer Drug Research (4)
United States (247) · France (78) · Canada (69) · Germany (61) · Italy (59) · Spain (58) · South Korea (48) · United Kingdom (47) · Netherlands (40) · Australia (37) · China (33) · Poland (30) · Belgium (29) · Taiwan (29) · Czechia (26)
Eric Jonasch, MD (3) · Robert J. Motzer, MD (3) · Amado Zurita, MD (2) · Andrew X. Zhu, MD (2) · Arun Rajan, M.D. (2) · Brian Rini (2) · Brian Rini, MD (2) · Dean F. Bajorin, MD (2) · Enrique Grande, MD (2)
PMID 37146227, PMID 25577718, PMID 27238653, PMID 28410911, PMID 33058158, PMID 33852135, PMID 17046465, PMID 20203173, PMID 23228446, PMID 26457466, PMID 29161241, PMID 29563634, PMID 29788981, PMID 32171288, PMID 32203306, PMID 32623479, PMID 33411058, PMID 33947608, PMID 37526095, PMID 10636102, PMID 11057895, PMID 11215292, PMID 12094370, PMID 12531805, PMID 12538485, PMID 12712448, PMID 15201427, PMID 15725919, PMID 16098458, PMID 16293410, PMID 16550259, PMID 16710031, PMID 16757724, PMID 17215529, PMID 17435538, PMID 17435539, PMID 17570676, PMID 18235122, PMID 19403935, PMID 19451429, PMID 19461405, PMID 19536893, PMID 19547919, PMID 19586800, PMID 19615940, PMID 19652072, PMID 20104222, PMID 20142724, PMID 20189981, PMID 20652398
2016 (6), 2008 (5), 2014 (5), U10CA031946 (5), 2015 (4), N01CM62201 (4), P30CA008748 (4), P30CA043703 (4), U10CA180821 (4), N01CM62203 (3), U01CA062502 (3), U10CA180820 (3), 2009 (2), 2017 (2), 2023 (2)